ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-OR10

BOOST KIDNEY: A Randomized Controlled Trial of Third Dose BNT162b2 vs. mRNA-1273 COVID-19 Vaccination in CKD and Dialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Yau, Kevin, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Chan, Christopher T., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Abe, Kento T., Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
  • Oliver, Matthew J., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
  • Levin, Adeera, BC Provincial Renal Agency, Vancouver, British Columbia, Canada
  • Gingras, Anne-Claude, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
  • Hladunewich, Michelle A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada

Due to waning humoral immunity, a third COVID-19 vaccine dose is recommended but there is a lack of evidence regarding whether there is benefit to homologous versus heterologous mRNA vaccination.


This was a multi-centre parallel group randomized controlled trial in Toronto, Ontario from September 30, 2021 to May 13, 2022 which enrolled participants with stage 3B-5 chronic kidney disease with prior homologous mRNA two dose vaccination. Overall 273 participants were randomized 1:1 to either 30µg BNT162b2 (n=137) or 100 µg mRNA-1273 (n=136) third dose stratified by initial vaccine type. Neutralizing antibodies against the B.1.1.529 (Omicron) variant of concern as well as binding SARS-CoV-2 IgG antibodies to the spike protein, receptor binding domain, and nucleocapsid protein were measured.


Participants had a median age of 67 years, 94% were on dialysis, 3% had prior COVID-19, and 59% had received BNT162b2 for initial two dose vaccination. Prior to the third vaccine dose, detectable Omicron neutralizing antibodies were present in 2% with BNT162b2 and 54% with mRNA-1273 two dose vaccination. At 1 month post third dose, among those with baseline BNT162b2, Omicron-specific neutralizing antibodies were detectable in 84% with third dose BNT162b2 in comparison to 83% with third dose mRNA-1273 (p=0.70). In those with baseline mRNA-1273, 100% receiving third dose mRNA-1273 had Omicron-specific neutralizing antibodies in comparison to 96% with third dose BNT162b2 (p=0.75). During the study period, 9.3% of participants (n=25) contracted COVID-19 and two died from COVID-19 with no difference in infection based on vaccine type (p=0.26).


In this randomized controlled trial of third dose COVID-19 vaccination, both homologous and heterologous vaccination elicited robust SARS-CoV-2 neutralizing antibody response.

Viral neutralization against wild-type, Delta, and Omicron variants of concern prior to third dose and 1 month following third dose BNT162b2 or mRNA-1273 vaccination.


  • Commercial Support –